Plasminogen activator inhibitor-1 (PAI-1) activity and retinal vascular calibre in type 2 diabetes

Diabetes Research and Clinical Practice

Volumn 87, Issue 2, 2010, Pages 192-199

  Brazionis, L ^a   Yau, J ^a   Rowley, K ^b   Itsiopoulos, C ^a   O'Dea, K ^a   Wong, T Y ^a   Jenkins, A ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b Centre for Health and Society   (Australia)

Author keywords

Cardiovascular risk factors; Diabetes; PAI 1; Retinal vascular calibre

Indexed keywords

ALBUMIN; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIGUANIDE; C REACTIVE PROTEIN; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FIBRIC ACID DERIVATIVE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HOMOCYSTEINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ORAL ANTIDIABETIC AGENT; PLASMINOGEN ACTIVATOR INHIBITOR 1; SULFONYLUREA;

ADULT; AGED; ARTERIOLE; ARTICLE; BIOCHEMISTRY; CAMERA; CARDIOVASCULAR RISK; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PROTEIN FUNCTION; RETINA BLOOD VESSEL; SYSTOLIC BLOOD PRESSURE; VENULE; WAIST HIP RATIO;

ADULT; AGED; AGED, 80 AND OVER; ARTERIOLES; BLOOD GLUCOSE; BLOOD PRESSURE; C-REACTIVE PROTEIN; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DIABETIC RETINOPATHY; FEMALE; HEART RATE; HEMOGLOBIN A, GLYCOSYLATED; HOMOCYSTEINE; HUMANS; MALE; MIDDLE AGED; PLASMINOGEN ACTIVATOR INHIBITOR 1; REGRESSION ANALYSIS; RETINAL ARTERY; RETINAL VEIN; RETINAL VESSELS; RISK FACTORS; VENULES; WAIST-HIP RATIO;

EID: 74449085790     PISSN: 01688227     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diabres.2009.11.007     Document Type: Article

References (34)

1. Wong T.Y., Islam F.M., Klein R., et al. Retinal vascular caliber, cardiovascular risk factors, and inflammation: the multi-ethnic study of atherosclerosis (MESA). Invest. Ophthalmol. Vis. Sci. 47 (2006) 2341-2350
2. Wong T.Y., Kamineni A., Klein R., et al. Quantitative retinal venular caliber and risk of cardiovascular disease in older persons: the cardiovascular health study. Arch. Intern. Med. 166 (2006) 2388-2394
3. Klein R., Klein B.E., Moss S.E., et al. The relation of retinal vessel caliber to the incidence and progression of diabetic retinopathy: XIX: the wisconsin epidemiologic study of diabetic retinopathy. Arch. Ophthalmol. 122 (2004) 76-83
4. Sun C., Liew G., Wang J.J., et al. Retinal vascular caliber, blood pressure, and cardiovascular risk factors in an Asian population: the Singapore Malay eye study. Invest. Ophthalmol. Vis. Sci. 49 (2008) 1784-1790
5. Liew G., Wang J.J., Duncan B.B., et al. Low birthweight is associated with narrower arterioles in adults. Hypertension 51 (2008) 933-938
6. Brazionis L., Rowley K., Jenkins A., Itsiopoulos C., and O'Dea K. Plasminogen activator inhibitor-1 activity in type 2 diabetes. A different relationship with coronary heart disease and diabetic retinopathy. Arterioscler. Thromb. Vasc. Biol. (2008) 10:1161/ATVBAHA.107.160168
7. Giles G.G. Epidemiology of food and disease: the Melbourne cohort study. Asia Pac. J. Clin. Nutr. 13 (2004) S30
8. World Health Organization (WHO). Diabetes Mellitus: Report of a WHO Study Group. (1999), World Health Organization, Geneva
9. Callaway C.W. Obesity. Public Health Rep. 102 (1987) 26-29
10. Wong T.Y., Knudtson M.D., Klein R., Klein B.E., Meuer S.M., and Hubbard L.D. Computer-assisted measurement of retinal vessel diameters in the beaver dam eye study: methodology, correlation between eyes, and effect of refractive errors. Ophthalmology 111 (2004) 1183-1190
11. Wong T.Y. Is retinal photography useful in the measurement of stroke risk?. Lancet Neurol 3 (2004) 179-183
12. Parr J.C., and Spears G.F. General caliber of the retinal arteries expressed as the equivalent width of the central retinal artery. Am. J. Ophthalmol. 77 (1974) 472-477
13. Hubbard L.D., Brothers R.J., King W.N., et al. Methods for evaluation of retinal microvascular abnormalities associated with hypertension/sclerosis in the atherosclerosis risk in communities study. Ophthalmology 106 (1999) 2269-2280
14. Refsum H., Smith A.D., Ueland P.M., et al. Facts and recommendations about total homocysteine determinations: an expert opinion. Clin. Chem. 50 (2004) 3-32
15. Wong T.Y., Shankar A., Klein R., and Klein B.E. Retinal vessel diameters and the incidence of gross proteinuria and renal insufficiency in people with type 1 diabetes. Diabetes 53 (2004) 179-184
16. Agirbasli M. Pivotal role of plasminogen-activator inhibitor 1 in vascular disease. Int. J. Clin. Pract. 59 (2005) 102-106
17. Nagi D.K., Mohamed Ali V., Jain S.K., Walji S., and Yudkin J.S. Plasminogen activator inhibitor (PAI-1) activity is elevated in Asian and Caucasian subjects with non-insulin-dependent (type 2) diabetes but not in those with impaired glucose tolerance (IGT) or non-diabetic Asians. Diabet. Med. 13 (1996) 59-64
18. Hirano T., Kashiwazaki K., Moritomo Y., Nagano S., and Adachi M. Albuminuria is directly associated with increased plasma PAI-1 and factor VII levels in NIDDM patients. Diabetes Res. Clin. Pract. 36 (1997) 11-18
19. Szelag B., Wroblewski M., Castenfors J., et al. Obesity, microalbuminuria, hyperinsulinemia, and increased plasminogen activator inhibitor 1 activity associated with parasympathetic neuropathy in type 2 diabetes. Diabetes Care 22 (1999) 1907-1908
20. Kawagishi T., Matsuyoshi M., Emoto M., et al. Impaired endothelium-dependent vascular responses of retinal and intrarenal arteries in patients with type 2 diabetes. Arterioscler. Thromb. Vasc. Biol. 19 (1999) 2509-2516
21. Funk M., Endler G., Exner M., et al. PAI-1 4G/5G insertion/deletion promoter polymorphism and microvascular complications in type 2 diabetes mellitus. Wien. Klin. Wochenschr. 117 (2005) 707-710
22. Nagi D.K., Knowler W.C., Hanson R.L., Ali V.M., and Yudkin J.S. Plasminogen activator inhibitor (PAI-1) and non-insulin-dependent diabetes in Pima Indians, south Asians and Europeans. Populations at varying risk of NIDDM and coronary artery disease. Thromb. Haemost. 75 (1996) 921-927
23. Astrup A.S., Tarnow L., Pietraszek L., et al. Markers of endothelial dysfunction and inflammation in type 1 diabetic patients with or without diabetic nephropathy followed for 10 years: association with mortality and decline of glomerular filtration rate. Diabetes Care 31 (2008) 1170-1176
24. Bosnyak Z., Forrest K.Y., Maser R.E., Becker D., and Orchard T.J. Do plasminogen activator inhibitor (PAI-1) or tissue plasminogen activator PAI-1 complexes predict complications in Type 1 diabetes: the Pittsburgh epidemiology of diabetes complications study. Diabet. Med. 20 (2003) 147-151
25. Nagi D.K., McCormack L.J., Mohamed-Ali V., Yudkin J.S., Knowler W.C., and Grant P.J. Diabetic retinopathy, promoter (4G/5G) polymorphism of PAI-1 gene, and PAI-1 activity in Pima Indians with type 2 diabetes. Diabetes Care 20 (1997) 1304-1309
26. Latron Y., Chautan M., Anfosso F., et al. Stimulating effect of oxidized low density lipoproteins on plasminogen activator inhibitor-1 synthesis by endothelial cells. Arterioscler. Thromb. 11 (1991) 1821-1829
27. Morange P.E., Aubert J., Peiretti F., et al. Glucocorticoids and insulin promote plasminogen activator inhibitor 1 production by human adipose tissue. Diabetes 48 (1999) 890-895
28. Morange P.E., Alessi M.C., Verdier M., Casanova D., Magalon G., and Juhan-Vague I. PAI-1 produced ex vivo by human adipose tissue is relevant to PAI-1 blood level. Arterioscler. Thromb. Vasc. Biol. 19 (1999) 1361-1365
29. Ersoy C., Kiyici S., Budak F., et al. The effect of metformin treatment on VEGF and PAI-1 levels in obese type 2 diabetic patients. Diabetes Res. Clin. Pract. 81 (2008) 56-60
30. Jenkins A.J., Li W., Moller K., et al. Pre-enrichment of modified low density lipoproteins with alpha-tocopherol mitigates adverse effects on cultured retinal capillary cells. Curr. Eye Res. 19 (1999) 137-145
31. Klein R.L., Semler A.J., Baynes J.W., Thorpe S.R., Lyons T.J., and Jenkins A.J. Glycation does not alter LDL-induced secretion of tissue plasminogen activator and plasminogen activator inhibitor-1 from human aortic endothelial cells. Ann. N. Y. Acad. Sci. 1043 (2005) 379-389
32. Eisenberg S. Lipoproteins, cholesterol ester transport and atherogenesis. Monogr. Atheroscler. 14 (1986) 107-112
33. Miyazaki H., Ogiku T., Sai H., Ohmizu H., Murakami J., and Ohtani A. Design, synthesis, and evaluation of orally active inhibitors of plasminogen activator inhibitor-1 (PAI-1) production. Bioorg. Med. Chem. Lett. 18 (2008) 6419-6422
34. Vaughan D.E., De Taeye B.M., and Eren M. PAI-1 antagonists: predictable indications and unconventional applications. Curr. Drug Targets 8 (2007) 962-970